Following publication of the Editorial by Rita Khoury, Rebecca Ibrahim, Tony Ibrahim, Axel Le Cesne and Tarek Assi, titled “NALIRIFOX in the upfront setting of metastatic pancreatic cancer: can FOLFIRINOX finally be dethroned?”, which appeared in the March issue of Future Oncology (Future Oncology [Lond.] 19[09], 617–620 [2023]; DOI: 10.2217/fon-2023-0088), it has been brought to our attention that reference 20 appeared incorrectly.
Reference 20 was previously displayed as: Chun JW, Lee SH, Kim JS et al. Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach. BMC Cancer 21(1), 537 (2021).
However, it should read as: Tossey JC, Reardon J, VanDeusen JB et al. Comparison of conventional versus liposomal irinotecan in combination with fluorouracil for advanced pancreatic cancer: a single-institution experience. Med Oncol 36(10), 87 (2019).
The authors of Future Oncology would like to sincerely apologise for any confusion or inconvenience this may have caused our readers.